Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.

Item

http://www.wikidata.org/entity/Q37959155

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Evaluating the risk-benefit profile of the direct-acting P2Y

@nl

Evaluating the risk-benefit pr ...... r in acute coronary syndromes.

@en

type

Item

label

Evaluating the risk-benefit profile of the direct-acting P2Y

@nl

Evaluating the risk-benefit pr ...... r in acute coronary syndromes.

@en

prefLabel

Evaluating the risk-benefit profile of the direct-acting P2Y

@nl

Evaluating the risk-benefit pr ...... r in acute coronary syndromes.

@en

P1476

Evaluating the risk-benefit pr ...... r in acute coronary syndromes.

@en

P2093

Steen Husted

http://www.w3.org/2001/XMLSchema#string

P2860

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Aspirin and clopidogrel resistance

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention

The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electroca

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

P304

79-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3810/PGM.2011.11.2498

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22104457

http://www.w3.org/2001/XMLSchema#string